Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn if one year of treatment with parathyroid hormone (PTH),
either alone or with risedronate, will increase the thickness of the bones in the hip and
spine in subjects with osteoporosis from chronic low dose steroid use. During the second
year, the study will also look at whether taking risedronate will preserve the bone thickness
created by one year of rhPTH 1-34 treatment.